Corcept Therapeutics (CORT) FCF Margin (2016 - 2025)
Historic FCF Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 26.24%.
- Corcept Therapeutics' FCF Margin fell 130200.0% to 26.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.01%, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of 29.02% for FY2024, which is 27100.0% up from last year.
- According to the latest figures from Q3 2025, Corcept Therapeutics' FCF Margin is 26.24%, which was down 130200.0% from 22.57% recorded in Q2 2025.
- Over the past 5 years, Corcept Therapeutics' FCF Margin peaked at 50.5% during Q3 2021, and registered a low of 3.2% during Q1 2025.
- Over the past 5 years, Corcept Therapeutics' median FCF Margin value was 32.37% (recorded in 2022), while the average stood at 30.18%.
- As far as peak fluctuations go, Corcept Therapeutics' FCF Margin tumbled by -308500bps in 2022, and later soared by 284800bps in 2024.
- Corcept Therapeutics' FCF Margin (Quarter) stood at 49.95% in 2021, then plummeted by -35bps to 32.37% in 2022, then tumbled by -87bps to 4.35% in 2023, then surged by 655bps to 32.83% in 2024, then dropped by -20bps to 26.24% in 2025.
- Its last three reported values are 26.24% in Q3 2025, 22.57% for Q2 2025, and 3.2% during Q1 2025.